Home » Newsletters » BioWorld Science

BioWorld Science

July 11, 2019

View Archived Issues

New insights into old Fountain of Youth

Preclearance boosts immunotherapy in pancreatic cancer

New vaccine protects nonhuman primates against equine encephalitis viruses

Preclinical evaluation of enzymatically cleavable lipoglycopeptides for pulmonary MRSA

FDA clears Syndax's IND for phase I/II trial of SNDX-5613 for relapsed/refractory acute leukemias

First patient dosed in phase II study of KD-025 in cutaneous systemic sclerosis

Researchers develop CRISPR/Cas9 hemophilia A murine model

Guangdong Newopp Biopharmaceuticals presents new arginase inhibitors

Chiesi discovers Rho kinase inhibitors

New PD-1/PD-L1 interaction inhibitors described by Yangtze River, Shanghai Haiyan

Chengdu Huajian Future Technology patents IDO-1 inhibitors

New catalytic system allows selective cancer cell targeting

Roche describes new hepatitis B virus cccDNA formation inhibitors

Myovant Sciences presents phase II data on MVT-602 in premenopausal women

CB2 receptor PET radiotracer [11C]MDTC evaluated in first-in-human study

Equillium initiates phase Ib trial of itolizumab in uncontrolled moderate to severe asthma

Transgene gains U.K. MHRA approval for phase I study of TG-4050 for head and neck cancer

STAT3 could be a novel target for treating endometriosis

BioMarck reports phase II data on BIO-11006 in NSCLC

Radiolabeled GRP-R antagonist [177Lu]RM-2 evaluated in advanced prostate cancer patients

Regeneron studies REGN-5713-5714-5715 in healthy adults and subjects with birch pollen allergy

Novel collagen-targeted PET tracer: safety, distribution and detection of collagen deposition in IPF

Organotrifluoroborate as a theranostic synthon for PET imaging-guided BNCT

Preclinical and first-in-human studies of [18F]DASA-23, a radiopharmaceutical for glioblastoma

SO-C101 begins first-in-human study in advanced/metastatic solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.